As previously communicated, Cline Scientific AB is taking part in a collaboration with AstraZeneca to utilize Cline's gradient technology as part of the multi-country European MSCA-ITN network, V.A Cure project. The parties have now agreed to continue this collaboration through 2022.

The collaboration began in January 2021 and has been focused on using Cline's gradient surface technology and methodology to develop protocols for differentiation of induced pluripotent stem (iPS) cells into cell types relevant for the repair and treatment of vascular anomalies. Creating such cell types will allow researchers to understand the core mechanisms of vascular disease and help to develop new treatments. 

About V.A Cure
V.A Cure is a Horizon 2020 funded project that aims to uncover core mechanisms of vascular anomalies and leverage this information to establish new therapeutics for vascular disease. The project consists of 14 individual research projects across seven academic labs and two industry partners. 

Vascular anomalies are defects of the vascular system that can be either with blood or lymph vessels. Many vascular anomalies are congenial and inherited, but they can also be brought on by events such as trauma and pregnancy. In addition, vascular anomalies can be malformations or tumors, ranging from harmless to life-threatening. 

Cline Scientific is a member of AstraZeneca's BioVentureHub in Gothenburg, Sweden. 

For more information about V.A Cure, follow the link to https://vacure.eu/. 

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com 
Phone: +46 0703585088
 

Cline Scientific AB (publ)                                                 Phone: 031-387 55 55
Argongatan 2 C                                                                   Email: info@clinescientific.com
431 53  MÖLNDAL                                                              Website: www.clinescientific.com

About Cline Scientific
Cline Scientific develops advanced cancer diagnostics and regenerative medicine treatments. The company is working heavily with R&D through joint collaborations with pharmaceutical companies and academic researchers around the world. The focus is on projects in the cancer diagnostic and stem cell therapy fields since Clines nanotechnology here provides unmet solutions to critical challenges and functions. The unique patented surface nanotechnology is used in cell-based products and processes to drive projects within Life Science into and through the clinical phase.

https://news.cision.com/cline/r/cline-scientific-extends-collaboration-agreement-with-astrazeneca,c3487065

https://mb.cision.com/Main/12114/3487065/1521113.pdf

(c) 2022 Cision. All rights reserved., source Press Releases - English